(E)-N-ethyl-3-(2-methoxyphenyl)acrylamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-N-ethyl-3-(2-methoxyphenyl)acrylamide
• 英文别名: N-ethyl-3-(2-methoxyphenyl)prop-2-enamide；(E)-N-ethyl-3-(2-methoxyphenyl)prop-2-enamide
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: GIWHXDDDRAIVFD-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  邻甲氧基苯甲醛 在 哌啶 、 吡啶 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 (E)-N-ethyl-3-(2-methoxyphenyl)acrylamide
  参考文献：
  名称：

  Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson’s disease via the activation of Nrf2/keap1 pathway

  摘要：

  Parkinson's disease (PD) is a slowly progressive and complex neurodegenerative disorder. Up to date, there are no approved drugs that could slow or reverse the neurodegenerative process of PD. Here, we reported the synthesis of series of piperine analogues and the evaluation of their neuroprotective effects against hydrogen peroxide (H2O2) induced damage in the neuron-like PC12 cells. Among these analogues, 3b exhibited the most potent protection effect and its underlying mechanism was further investigated. Further results indicated that the ROS scavenging and cytoprotection effect of 3b might be related to the Nrf2 activation and upregulation of related phase II antioxidant enzymes, such as HO-1 and NQO1. In in vivo study, oral administration (100 mg/kg) of 3b significantly attenuated PD-associated behavioral deficits in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD and protected tyrosine hydroxylase-immunopositive dopaminergic neurons. Our results provided evidence that 3b might be a promising candidate for Parkinson's disease treatment. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112385

文献信息

• HIGH ACTIVITY STING PROTEIN AGONIST
  申请人：Adlai Nortye Biopharma Co., Ltd.

  公开号：EP3842437A1

  公开（公告）日：2021-06-30

  The present disclosure provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using compounds of Formula (I) to prevent and/or treat immune-related disorders.

  本公开提供了式（I）化合物、其药物组合物以及使用式（I）化合物预防和/或治疗免疫相关疾病的方法。
• Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson’s disease via the activation of Nrf2/keap1 pathway
  作者：Lun Wang、Xiaoying Cai、Mingsong Shi、Linlin Xue、Shuang Kuang、Ruiling Xu、Wenyan Qi、Yan Li、Xu Ma、Ruijia Zhang、Feng Hong、Haoyu Ye、Lijuan Chen

  DOI：10.1016/j.ejmech.2020.112385

  日期：2020.8

  Parkinson's disease (PD) is a slowly progressive and complex neurodegenerative disorder. Up to date, there are no approved drugs that could slow or reverse the neurodegenerative process of PD. Here, we reported the synthesis of series of piperine analogues and the evaluation of their neuroprotective effects against hydrogen peroxide (H2O2) induced damage in the neuron-like PC12 cells. Among these analogues, 3b exhibited the most potent protection effect and its underlying mechanism was further investigated. Further results indicated that the ROS scavenging and cytoprotection effect of 3b might be related to the Nrf2 activation and upregulation of related phase II antioxidant enzymes, such as HO-1 and NQO1. In in vivo study, oral administration (100 mg/kg) of 3b significantly attenuated PD-associated behavioral deficits in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD and protected tyrosine hydroxylase-immunopositive dopaminergic neurons. Our results provided evidence that 3b might be a promising candidate for Parkinson's disease treatment. (C) 2020 Elsevier Masson SAS. All rights reserved.